Jan Deadline For API QR Codes In India Arrives; Are Local, Chinese Firms Prepared?
Formulations To Follow In August
Executive Summary
Beginning January, packaging on active pharmaceutical ingredients (APIs) made in or imported into India is to bear a QR code, but the Indian industry is unprepared and feels the move isn’t beneficial. With about 70% of the country’s API imports coming from China, questions remain on its implementation too
You may also be interested in...
Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies
As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.
A Year Of Paxlovid - Where Is The Licensed Generic?
It’s been a year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir. Scrip looks at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023 as Hetero's version becomes the first with WHO Prequalification while two Chinese and a Korean company wait in the wings.